NASDAQ$HROW

Harrow Inc · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Reported results for the first quarter 2020.

Harrow Health reported its first quarter 2020 results, with management expressing excitement about the ImprimisRx team's role in providing for physician customers and improving health outcomes as the economy reopens.

  • Harrow Health published its first quarter 2020 letter to stockholders.
  • CEO Mark L. Baum is excited about the ImprimisRx team getting back to being a trusted provider to physician customers.
  • The company is starting to see orders come in as customers re-open.
  • Harrow Health is excited about upcoming events, catalysts, and developments in the near and long-term.

Headline financials

Total Revenue

$11.8M

Previous: $12.3M-3.8%
EPS (adj)

-$0.50

Previous: $0.43-216.3%
Capital Expenditures

-$220K

Previous: -$213K-3.3%
Free Cash Flow

-$13.1M

Previous: $11.1M-217.8%
Net Income

-$12.9M

Previous: $11.4M-213.6%
Operating Income

-$628K

Previous: -$556K-12.9%
Gross Profit

$8.19M

Previous: $8.39M-2.4%
Cash & Equivalents

$4.12M

Previous: $4.27M-3.3%
Total Assets

$46.9M

Previous: $66.5M-29.5%
Stock-Based Comp

$533K

Previous: $713K-25.2%

Revenue & EPS history

Harrow · Revenue · Quarterly

$11.8M

Q1 2020-3.8%vs Q1 2019
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

+1.6%

Avg return

Earnings day

+3.0%

Avg return

5 days after

+8.7%

Avg return

30 days after

52%

25 / 48 earnings

Positive

+49.3%

Q2 2024

Best reaction

-36.0%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.4%-18.5%
Q4 2025+2.3%-32.2%-34.1%
Q3 2025+13.6%+19.5%+49.7%
Q1 2025+3.4%+6.5%+25.4%
Q4 2024-6.0%+21.8%+2.9%
Q3 2024-14.1%-23.9%-28.9%
Q2 2024+49.3%+56.3%+67.2%
Q1 2024+40.0%+44.5%+57.3%
Q4 2023+0.3%+9.6%+3.4%
Q3 2023-36.0%-30.2%-21.7%
Q2 2023-17.4%-14.7%-26.8%
Q1 2023-20.5%-24.1%-26.9%
Q4 2022+6.7%+22.9%+42.6%
Q3 2022-4.2%-9.4%+10.5%
Q2 2022+12.2%+24.6%+32.6%
Q1 2022+3.3%-5.3%+15.3%
Q4 2021+3.0%-1.4%-1.7%
Q3 2021-4.9%-3.3%-21.1%
Q2 2021-0.3%-0.8%+13.0%
Q1 2021+15.8%+14.5%+14.0%
Q4 2020+3.5%+3.4%-12.3%
Q3 2020+25.8%+30.0%+19.9%
Q2 2020+4.8%+10.4%+15.0%
Q1 2020-5.8%-9.7%+36.5%
Q4 2019-7.5%-16.0%-3.8%
Q3 2019+18.6%+16.1%+33.8%
Q2 2019-23.6%-21.7%-8.0%
Q1 2019+10.1%+16.5%+26.6%
Q4 2018-7.5%-20.3%-30.1%
Q3 2018+7.2%+23.0%+38.4%
Q2 2018+13.4%+29.3%+26.4%
Q1 2018+9.3%+5.3%+6.2%
Q4 2017-3.4%-5.3%-3.9%
Q3 2017+5.7%+19.1%+7.6%
Q2 2017-7.9%-9.7%-28.2%
Q1 2017-4.8%-12.6%-22.5%
Q4 2016+2.9%+17.0%+79.7%
Q3 2016-9.8%-13.2%-28.9%
Q2 2016-3.1%-2.6%+6.5%
Q1 2016+1.9%
Q4 2015-2.2%
Q3 2015-6.2%
Q2 2015-1.3%
Q1 2015+1.3%
Q4 2014+3.5%
Q3 2014-2.7%
Q2 2014+7.8%
Q2 2010-1.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro